Prognostic Value of Peripheral Blood Parameters in Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer - Top-Institutions - MDSpire

Prognostic Value of Peripheral Blood Parameters in Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer

By
Tae-in Yoon
Seunghee Baek
Ji hyeon Lee
Tae Kyung Yoo
Jisun Kim
Il Yong Chung
Beom Seok Ko
Hee Jeong Kim
Jong Won Lee
Byung Ho Son
Sae Byul Lee
January 3, 2026
0 min

Bmc Cancer

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

MD Anderson Cancer Center

Houston, TX
Key Differentiators
- Breast Oncology
- Cancer Immunology
- Translational Research
#2

Dana-Farber Cancer Institute

Boston, MA
Key Differentiators
- Breast Oncology
- Cancer Immunology
- Hematology
#3

Memorial Sloan Kettering Cancer Center

New York, NY
Key Differentiators
- Breast Surgical Oncology
- Medical Oncology
- Cancer Biomarkers
#4

Johns Hopkins Medicine

Baltimore, MD
Key Differentiators
- Breast Oncology
- Cancer Biomarkers
- Hematology
#5

University of California, San Francisco (UCSF) Medical Center

San Francisco, CA
Key Differentiators
- Breast Oncology
- Cancer Immunology
- Clinical Research

Original Source(s)

Bmc Cancer

Prognostic Value of Peripheral Blood Parameters in Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer

by Tae-in Yoon, Seunghee Baek, Ji hyeon Lee, Tae Kyung Yoo, Jisun Kim, Il Yong Chung, Beom Seok Ko, Hee Jeong Kim, Jong Won Lee, Byung Ho Son, Sae Byul Lee
January 3, 2026

Related Content

Frontiers In Oncology

Synthetic short RNA in cancer

by Takeshi Tomita, Kentaro Minagawa, Sachie Hiratsuka
May 28, 2026

Frontiers In Endocrinology

Case Report: First description of an intracranial “NET” in ROHHAD syndrome; time to rename to the ROHHAD-NeCT syndrome?

Frontiers In Oncology

VANGL1 links angiogenesis–stemness programs and tumor microenvironment remodeling: a pan-cancer, multi-omics study with translational validation